Search Results

• 1905585974

  A Feasibility Clinical Trial of Exablate for Low Intensity Focused Ultrasound Neuromodulation in Patients with Opioid Use Disorder (OUD) and/or other Substance Use Disorders (SUDs)

• 1910761036

  Evaluation of retinal imaging as a predictive marker in Alzheimer's disease

• 1911792590

  Feasibility of Using Wearable Device Technology in understanding sleep stages

• 20200469

  A Phase 1b Study Evaluating the Safety and Efficacy of First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects with Extensive Stage Small Cell Lung Cancer

• 20324

  ON-TRK: PrOspective Non-Interventional Study in Patients with Locally Advanced or Metastatic TRK Fusion Cancer Treated with Larotrectinib

• 21-054-TRP

  Prospera Test Evaluation in Cardiac Transplant (ProTECT)

• 21-101

  An Evaluation of the Safety and Effectiveness of the Conformal CLAAS System for Left Atrial Appendage Occlusion

• 2101221058

  Treating the Whole Patient: Measuring Distress in Prosthetic Join Infection Using a Standardized Metric CRUTCH Pathway Pilot

• 2102248177

  Waterproof casting versus standard casting for short leg walking casts: a prospective randomized controlled trial

• 2103270150

  The Longitudinal Assessment of Physiological, Cognitive, and Behavioral Characteristics of Patients with Substance Use Disorders via Wearable Technologies and Ecological Momentary Assessment

• 213824

  A Phase 2, Randomized, Open-label, Platform Study Utilizing a Master Protocol to Evaluate Novel Immunotherapy Combinations in Participants with Previously Untreated, Locally Advanced/Metastatic, Programmed Death Ligand 1-Selected Non-Small-Cell Lung Cancer

• 2201501642

  Evaluation of Wearable Technology for Chronic Stress and Burnout

• 2205578041

  Feasibility of Wearable Device Technology in Patients with Inflammatory Bowel Disease

• 2205578909

  Investigating human cognition with medically necessary intracranial electrophysiologic recordings

• 2206599818

  Pilot study to standardize visual cues and cognitive tasks for substance use disorder

• 2207611017

  Assessment of Memory and its Neural Correlates Using Functional Magnetic Resonance Imaging

• 2209649302

  Feasibility of Wearables Technology in patients with Relapsing Remitting Multiple Sclerosis

• 2210661731

  Role of Wearable Devices and Data Analytics in Developing Tools for Early Diagnosis and Prognosis of Movement Disorders

• 2212689886

  RANDOMIZED TRIAL COMPARING ENDOSCOPIC ULTRASOUND-GUIDED GASTROJEJUNOSTOMY AND SURGICAL GASTROJEJUNOSTOMY IN GASTRIC OUTLET OBSTRUCTION

• 2303735843

  The Utilization of Machine Learning Technologies in Predicting Relapse: Identifying Risk Factors and Implementing Intervention Before Drug Use Occurs

• 2303738136

  Evaluation of Photobiomodulation or dry float therapy on sleep quality in middle-aged and elderly individuals.

• 2304754574

  Development of diagnostic tests for concussion in virtual reality

• 2305778641

  Imaging studies in Dementia and Neurodegenerative Diseases

• 2305791111

  The Utilization of Wearable Technology and Ecological Momentary Assessment for Real-time Monitoring of Participants in Interventional Clinical Trials

• 2307822474

  Retrospective and prospective follow up study for patients who participated in interventional clinical trials for substance use disorders at RNI

• 2308834792

  The Feasibility of Wearables Technology in Understanding Memory Disorders

• A011-16

  A Phase 2, Double-blind, Randomized, Placebo controlled Study to Evaluate the Effects of Sotatercept versus Placebo for the Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension (Cpc-PH) due to Heart Failure with Preserved Ejection Fraction (HFpEF)

• A031704

  PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab vs VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer (PDIGREE)

• A041703

  A Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for PH-Negative CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults with Relapsed or Refractory Disease

• A051901

  Phase I Trial of Methotrexate, Rituximab, Lenalidomide, and Nivolumab (NIVO-MR2) Induction followed by Lenalidomide and Nivolumab Maintenance in Primary CNS Lymphoma

• A071601

  Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas

• A071702

  A Phase II Study of Checkpoint Blockade Immunotherapy in Patients with Somatically Hypermutated Recurrent Glioblastoma

• A081801

  Integration of Immunotherapy into Adjuvant Therapy for Resected NSCLC: ALCHEMIST CHEMO-IO

• A151216

  Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

• A151804

  Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events

• ACT-NOWS-WEANING

  Pragmatic, Randomized, Blinded Trial to Shorten Pharmacologic Treatment of Newborns with Neonatal Opioid Withdrawal Syndrome (NOWS)

• ACTUATE-1801

  Actuate 1801: Phase 1/2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3β) Inhibitor, as a Single Agent and Combined with Chemotherapy, in Patients with Refractory Hematological Malignancies or Solid Tumors

• AIRR-0010SIV

  A Multi-Center, Prospective Registry to Evaluate the Continued Safety and Effectiveness of Hand and Wrist Products

• ALXN1720-MG-301

  A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel, Multicenter Study to Evaluate the Safety and Efficacy of ALXN1720 in Adults with Generalized Myasthenia Gravis Protocol Number: ALXN1720-MG-301 IND Number: 150823

• AMAG-FER-CKD-354

  A Phase 3, Randomized, Open-Label, Multicenter Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects with Chronic Kidney Disease (CKD)

• APL-101-01

  Phase 1 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Advanced Solid Tumors and c-Met Dysregulation

• ASPIRE

  Anticoagulation in ICH Survivors for Stroke Prevention and Recovery

• BB2121-EAP-001

  Expanded Access Protocol (EAP) for Subjects Receiving Idecabtagene Vicleucel That is Nonconforming for Commercial Release

• BE1116-3006

  A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Large Simple Trial Evaluating the Use of BE1116 (4-Factor Prothrombin Complex Concentrate [Kcentra / Beriplex]) to Improve Survival in Patients with Traumatic Injury and Acute Major Bleeding

• BGS-21-01

  A Prospective, Randomized, Intra-Patient Controlled, Multi-Center Clinical Investigation evaluating OsteoAmp® Select Fibers versus Infuse(TM) Bone Graft as an autograft substitute in lumbar fusion procedures.

• BOOST-3

  Brain Oxygen Optimization in Severe Traumatic Brain Injury-Phase 3 (BOOST-3) A multicenter, randomized, blinded-endpoint, comparative effectiveness study of goal-directed critical care based upon monitoring of brain tissue oxygen and intracranial pressure versus monitoring of intracranial pressure alone in patients with severe traumatic brain injury.

• BPR-PIP-003

  A multicenter, open-label, single-arm, multiple-dose study to evaluate the safety, pharmacokinetics, and efficacy of ceftobiprole medocaril in term and pre-term neonates and infants up to 3 months of age with late-onset sepsis

• BREATHE

  The BREATHE Study: Bronchiolitis Recovery and the Use of High Efficiency Particulate Air (HEPA) Filter

• C-00044

  Prospective, Randomized, Double-Blind, Sham-Controlled, Multi-Center Pivotal Study to Evaluate the Efficacy and Safety of Duodenal Mucosal Resurfacing Using the Revita® System in Subjects with Type 2 Diabetes on Insulin therapy

• CAPTIVA

  Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis (CAPTIVA)

• CCTL019B2003I

  Managed Access Program (MAP) to provide access to CTL019, for acute lymphoblastic leukemia (ALL) in diffuse large b-cell lymphoma (DLBCL) patients with out of specification leukapheresis product and/or manufactured tisagenlecleucel out of specification for commercial release

• CMG2021-36H

  Multicenter, Prospective Post-Market Clinical Follow-Up Study of the G7® Freedom Constrained Vivacit-E® Liners

• COG-AALL1631

  International Phase 3 trial in Philadelphia chromosome-positive Acute Lymphoblastic Leukemia testing imatinib in combination with two different cytotoxic chemotherapy backbones.

• COG-AALL1731

  A Phase 3 Trial Investigating Blinatumomab (IND# 117467, NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy)

• COG-ACNS1422

  A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients

• COG-ACNS1833

  A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib (NSC# 748727, IND# 77782) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) not associated with BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)

• COG-AGCT1531

  A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors

• COG-AHEP1531

  COG-AHEP1531 - Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)

• COG-ALTE1631

  ALTE1631 - A Randomized Web-based Physical Activity Intervention among Children and Adolescents with Acute Lymphoblastic Leukemia

• COG-ANBL00B1

  Neuroblastoma Biology Studies

• COG-ANBL1821

  A Phase 2 Randomized Study of Irinotecan/Temozolomide/Dinutuximab with or without Eflornithine (DFMO) (IND# 141913) in Children with Relapsed, Refractory or Progressive Neuroblastoma

• COG-APEC14B1

  APEC14B1 - Project: EveryChild - A Registry, Eligibility Screening, Biology and Outcome Study.

• COMB157GUS10

  AGNOS: An 18-month, Open-label, Multi-Center Phase IV Study to Assess the Effect of Ofatumumab 20mg SC Monthly in Treatment Naïve, Very Early Relapsing Remitting Multiple Sclerosis Patients Benchmarked Against Healthy Controls on Select Outcomes

• COPAT

  Comparing Oral versus Parenteral Antimicrobial Therapy (COPAT) Trial

• CP-2021-05

  Left Atrial Appendage Exclusion for Prophylactic Stroke Reduction Trial

• CREST2

  Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial (CREST-2)

• CTN-0100

  Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD)

• CYP-001

  Copper Histidinate Treatment for Menkes Disease

• D8531C00002

  CAMBRIA-1: AA Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients with ER+/HER2- Early Breast Cancer and an Intermediate or High Risk of Recurrence Who Have Completed Definitive Locoregional Therapy and at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Without Disease Recurrence

• D926PC00001

  A Phase 3, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) Versus Investigator's Choice of Chemotherapy in Patients who are not Candidates for PD-1/PD-Ll Inhibitor Therapy in First-line Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast02)

• D926XC00001

  TROPION-Breast03: A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients with Stage I-III Triple-Negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy

• D9481C00001

  An open-label study to assess safety and efficacy of SZC in pediatric patients with hyperkalaemia

• DBSOUD02

  A Randomized, Sham-Controlled Trial Investigating Deep Brain Stimulation as a Novel Treatment for Refractory Opioid Use Disorder

• E4512

  A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fushion Protein

• EA2176

  A Randomized Phase III Study of Immune Checkpoint Inhibition with Chemotherapy in Treatment-Naïve Metastatic Anal Cancer Patients

• EA2185

  Comparing Two Methods to Follow Patients With Pancreatic Cysts

• EA2192

  APOLLO: A Randomized Phase II Double-Blind Study of Olaparib versus Placebo Following Curative Intent Therapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2, or PALB2 Mutation

• EA2197

  Optimal Perioperative Therapy for Incidental Gallbladder Cancer (OPT-IN): A Randomized Phase II/III Trial

• EA4151

  A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma In Minimal Residual Disease-Negative First Complete Remission

• EA5181

  Randomized Phase III Trial of MEDI4736 (durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC

• EA8171

  Multiparametric MRI (mpMRI) for Preoperative Staging and Treatment Planning for Newly-Diagnosed Prostate Cancer (Phase II)

• EA9171

  Phase II Study of Adding the Anti-PD-1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease

• EAA173

  Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma

• EAY191

  Molecular Analysis for Combination Therapy Choice (ComboMATCH)

• EAY191-N4

  A Randomized Trial of Selumetinib and Olaparib or Selumetinib Alone in Patients with Recurrent or Persistent RAS Pathway Mutant Ovarian and Endometrial Cancers: A ComboMATCH Treatment Trial

• EF-32

  A Pivotal Randomized, Open-Label Study of Optune (TTFields, 200KHZ) Concomitant with Radiation Therapy and Temozolomide for the Treatment of Newly Diagnosed Glioblastoma

• EPFL002

  Evaluating Subcortical Brain Structures in Response to Presence Hallucinations for Parkinson's Disease- EPFL

• FAST-REGISTRY

  Fast Registry Protocol: Prospective Observational Cohort Study of Fetal Atrial Flutter & Supraventricular Tachycardia

• GN41791

  A Phase III Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Patients with Primary Progressive Multiple Sclerosis

• GOG-3039

  A Phase II Study of Abemaciclib in Combination With Letrozole in Advanced, Recurrent or Metastatic Endometroid Endometrial Cancer

• GOG-3043

  A Randomized Controlled Trial of Robotic versus Open Radical Hysterectomy for Cervical Cancer (ROCC trial)

• GRAIL-MA-001

  REFLECTION: Real World Evidence for Learnings in Early Cancer Detection, a Clinical Practice Learning Program for Galleri

• HIE-RLS-0071

  A Phase 2, Two-Stage, Randomized, Double-Blind, Placebo-Controlled, Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of RLS0071 in Newborns with Moderate or Severe Hypoxic-Ischemic Encephalopathy Undergoing Therapeutic Hypothermia with Long-Term Follow-Up (STAR)

• HIFLO

  Parallel-group, prospective, randomized, controlled phase III trial of home High flow Nasal Therapy (HFNT) via myAirvo 3 plus usual COPD medical care vs. usual COPD medical care

• HLX10-005-SCLC301-E

  A Randomized, Open-label Study of HLX10 plus Chemotherapy (Carboplatin-Etoposide) in comparison with Atezolizumab plus Chemotherapy in Previously Untreated US Patients with Extensive Stage Small Lung Cancer (ES-SCLC)

• ICI-M-1201

  AbatacepT foR ImmUne checkpoint inhibitor associated Myocarditis (ATRIUM): A Phase 3, Investigator-Initiated, Randomized, Double- Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept Compared to Placebo in Hospitalized Participants with Immune Checkpoint Inhibitor Associated Myocarditis

• IMVT-1401-3202

  IMVT-1401-3202: A Phase 3, Multi-center, Randomized, Quadruple-masked, Placebo-controlled Study of Batoclimab for the Treatment of Participants with Active Thyroid Eye Disease

• INTRAGO-II

  A Multicenter Randomized Phase III Trial on Intraoperative Radiotherapy in Newly Diagnosed Glioblastoma Multiforme (INTRAGO II)

• JCAR017-EAP-001

  Expanded Access Protocol (EAP) for Subjects Receiving Lisocabtagene Maraleucel that is Nonconforming for Commercial Release

• KS10237

  Discontinuation of Continuous Renal Replacement Therapy in Patients with Acute Kidney Injury: A pilot quasi-experimental study

• LUNGMAP

  A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)

• M16-000

  A Multicenter, Randomized, Double-Blind, Placebo-Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Crohn's Disease Who Responded to Induction Treatment in M16-006 or M15-991.

• M19-977

  A Randomized, Active-Controlled, Efficacy Assessor-Blinded Study to Evaluate Pharmacokinetics, Safety and Efficacy of Risankizumab in Patients from 6 to Less than 18 Years of Age with Moderate to Severe Plaque Psoriasis

• M22-418

  A Phase 3 Multicenter 24-Week Open Label Study to Evaluate the Safety, Tolerability, and Efficacy of Atogepant When Added to OnabotulinumtoxinA (BOTOX) for the Preventive Treatment of Chronic Migraine

• MDT17074SD1706

  Prospective, Randomized, Controlled, Blinded Pivotal Study In Subjects Undergoing A Transforaminal Lumbar Interbody Fusion (TLIF) At One Or Two Levels Using Infuse Bone Graft and The Capstone Spinal System With Posterior Supplemental Fixation For The Treatment Of Symptomatic Degenerative Disease Of The Lumbosacral Spine

• MDT19014

  Electrically evoked compound action potentials human observation Medtronic system study (ECHO-MDT)

• MGT-GAD-025

  A Randomized, Double-Blind, Sham-Controlled Study to Evaluate the Safety and Tolerability of Glutamic Acid Decarboxylase Gene Transfer to the Subthalamic Nuclei in Participants with Parkinson s Disease

• MK3475-630-07

  A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Pembrolizumab Versus Placebo as Adjuvant Therapy Following Surgery and Radiation in Participants with High-risk Locally Advanced Cutaneous Squamous Cell Carcinoma

• MK7655A-021

  A Phase 2/3 Open-label, Randomized, Active-controlled Clinical Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of MK-7655A in Pediatric Participants From Birth to Less Than 18 Years of Age With Confirmed or Suspected Gram-negative Bacterial Infection

• MOVEUP

  Improving pediatric COVID-19 vaccine uptake using an mHealth tool: a randomized, controlled trial

• NCBP6637-01

  A Multicenter Safety Study of Unlicensed, Investigational Cryopreserved Cord Blood Units (CBUs) Manufactured by the National Cord Blood Program (NCBP) and Provided for Unrelated Hematopoietic Stem Cell Transplantation of Pediatric and Adult Patients

• NEURO

  RECOVER-NEURO: A Platform Protocol for Evaluation of Interventions for Cognitive Dysfunction in Post-Acute Sequelae of SARS-CoV-2 Infection (PASC)

• NN9535-4801

  Efficacy and safety of once-weekly semaglutide s.c. 2.0 mg as add-on to dose-reduced insulin glargine vs titrated insulin glargine in participants with type 2 diabetes and overweight

• NRG-CC005

  Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps (FORTE)

• NRG-CC008

  A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-Oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers (SOROCk)

• NRG-GI008

  Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US)

• NRG-GU009

  Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk with Radiation (PREDICT-RT*)

• NRG-GY019

  A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum

• NRG-GY026

  A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined with Either Trastuzumab and Hyaluronidase-OYSK (Herceptin Hylecta) or Pertuzumab, Trastuzumab, and Hyaluronidase-ZZXF (Phesgo) In HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma

• NRG-LU007

  Randomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial

• NSABP-B60

  A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study of Trastuzumab Deruxtecan (T-DXd) versus Trastuzumab Emtansine (T-DM1) in Subjects with High-Risk HER2-Positive Primary Breast Cancer Who Have Residual Invasive Disease in Breast or Axillary Lymph Nodes Following Neoadjuvant Therapy

• NSABP-FB12

  An Open-Label Phase II Trial to Evaluate the Efficacy and Safety of Neoadjuvant Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel Plus Trastuzumab and Pertuzumab in Early Stage HER2-Negative Breast Cancer Patients Selected with a Test Measuring Live Cell HER2 Signaling Transduction (FACT 1)

• PDS0101-HNC-201

  A Phase II, Open-Label, Multi-Center Study of PDS0101 (ImmunoMAPK-RDOTAP/HPV-16 E6 & E7 Peptides) and Pembrolizumab Combination Immunotherapy as a First Line Treatment in Subjects with Recurrent and/or Metastatic Head and Neck Cancer and High-Risk Human Papillomavirus-16 Infection

• PICU-UP

  Clinical Effectiveness of the "PICU Up!" Multifaceted Early Mobility Intervention for Critically Ill Children: A pragmatic, stepped-wedge trial

• PRIMARY-CTSN

  Percutaneous or Surgical Repair In Mitral Prolapse And Regurgitation for >65 Year-olds

• REV1

  Anticoagulation for New-Onset Post-Operative Atrial Fibrillation after CABG

• RM-493-035

  SETMELANOTIDE RM-493-035 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study: 5 Independent Sub-studies of Setmelanotide in Patients with POMC, PCSK1, LEPR, SRC1, SH2B1, and PCSK1 N221D Gene Defects in the Melanocortin-4 Receptor Pathway

• RNI-NMD-AD01

  Early Feasibility Study of Low-Intensity Focused Ultrasound (LIFU) Neuromodulation in Patients with Mild Cognitive Impairment (MCI) due to Alzheimer's Disease

• RPC-1063-MS-001

  A Multicenter, Longitudinal, Open-Label, Single-Arm Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated with Ozanimod (RPC-1063)

• RTOG1216

  Randomized Phase II/III Trial of Adjuvant Radiation Therapy with Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck

• S1501

  Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer, Phase III

• S1706

  A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer

• S1802

  Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer

• S1806

  Phase III Randomized Trial of Concurrent Chemoradiotherapy with or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer

• S1827

  MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)

• S1900E

  A Phase II Study of AMG 510 in Participants with Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN LUNGMAP Sub-Study)

• S1905

  A Phase I/II Study of AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) in Patients with Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) / T-Cell Lymphoblastic Lymphoma (T-LBL)

• S1914

  A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC

• S2013

  Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study

• S21-01226

  NIH RECOVER A Multi-site Observational Study: Study of Long COVID in Adults

• S2107

  Randomized Phase II trial of encorafenib and cetuximab with or without nivolumab (NSC #748726) for patients with previously treated, microsatellite stable, BRAFV600E metastatic and/or unresectable colorectal cancer

• S2302

  PRAGMATICA - LUNG: A Prospective Randomized Study of Ramucirumab (LY3009806; NSC 749128) Plus Pembrolizumab (MK-3475; NSC 776864) Versus Standard of Care for Participants Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer

• SATURN

  STATINS USE IN INTRACEREBRAL HEMORRHAGE PATIENTS

• SDI-PMX-NA003

  A Prospective, Multicenter, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of PMX Cartridge in Addition to Standard Medical Care for Patients with Endotoxemic Septic Shock: TIGRIS Trial

• SLEEPSMART

  Sleep for Stroke Management And Recovery Trial

• SLT-THERAPY

  Clarifying The Optimal Application of SLT Therapy

• SSWAB-IT

  Assessing accuracy and reliability of self-obtained respiratory cultures, and implementation of processes for using home respiratory cultures in clinical care.

• T-INVENT-001

  Post-Market Clinical Follow-up Registry of Patients Requiring Nerve Gap Repair from Integra

• TIGER-PAC

  Targeted Intra-arterial Gemcitabine vs Continuation of IV Gemcitabine plus Nab-Paclitaxel following Induction with sequential IV Gemcitabine plus Nab-Paclitaxel and Radiotherapy for Unresectable Locally Advanced Pancreatic Cancer

• TSOG101

  Study to Evaluate Perioperative Circulating Tumor DNA as a Prognostic Biomarker in Patients Undergoing Neoadjuvant Therapy for Resectable Non-small Cell Lung Cancer

• VGN-TED-301

  A Phase 2b, Randomized, Double-Mask, Placebo Controlled, Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Linsitinib in Subjects with Active, Moderate to Severe Thyroid Eye Disease

• VITAL

  A Platform Protocol for Evaluation of Interventions for Viral Persistence, Viral Reactivation, and Immune Dysregulation in Post-Acute Sequelae of SARS-CoV-2 Infection (PASC)

• VX20-121-103

  A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-121 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous for F508del or Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation

• VX20-121-104

  A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic Fibrosis

• WVU010120

  Pioglitazone Therapy Targeting Fatigue in Breast Cancer

• WVU010220

  Phase I/II Study of Neoadjuvant FOLFIRINOX in Combination with Peri-Operative Oral Hydroxychloroquine (FHQ) in Subjects with Resectable Adenocarcinoma of the Pancreas

• WVU010320

  A Phase I/II study of Radiation/Temozolomide and Immunotherapy with Daratumumab to Improve Antitumor Efficacy in Glioblastoma (PRIDE)

• WVU011115

  Skeletal Muscle Tissue Procurement for the Study of Breast Cancer -Associated Gene Expression

• WVU011118

  Measurement of the Partial Pressure of Oxygen in Cutaneous Tumors Using Electron Paramagnetic Resonance (EPR) Oximetry

• WVU01HSC20

  An Open-Label Trial of Repetitive Transcranial Magnetic Stimulation for Opioid Use Disorder

• WVU01HSC21

  Assessing WVU's Multidisciplinary Infusion Service through Patients' Perspectives

• WVU01HSC23

  A randomized clinical trial to determine the effect of transient postoperative urinary retention using Sugammadex (4 mg x kg) versus glycopyrrolate and neostigmine (0.01 mg/kg – 50mg/kg) in patients undergoing vaginal hysterectomies with and without pelvic organ prolapse procedures. A pilot study

• WVU020220

  Safety and Feasibility of Prophylactic Heated Intra-peritoneal Chemotherapy (HIPEC) for High-Risk Gallbladder Adenocarcinoma

• WVU02HSC23

  A pilot study investigating the correlation between circulating cell-free mitochondria and fatigue in multiple sclerosis patients.

• WVU03HSC21

  Influence of Scaling and Root Planing with Minocycline Microspheres on the Composition and Functional Characteristics of Subgingival Microbiome Communities

• WVU03HSC23

  Role of Cytb5R1 and Dcytb on oxidative stress in ulcerative colitis human colon

• WVU04HSC23

  Change in Fructosamine before and one month after the bariatric surgery predict weight loss, six months after surgery.

• WVU05HSC21

  Exploring the Impact of Intimate Partner Violence on Engagement in Care Among People Living with HIV in West Virginia.

• WVU06HSC18

  Self-Management Intervention in Adolescents with Recurrent Headache

• WVU09HSC21

  Identification of Biomarkers for Inflammatory Bowel Disease

• WVU11HSC21

  Basal ganglia resting state functional connectivity in opioid use disorder; Neuroimaging of Brain Injury Recovery

• WVU13HSC20

  Effects of Blocking Blue Light at Night on Patient Outcomes after Elective CABG Surgery

• WVU13HSC21

  Evaluation of Group Obesity Therapy Implementation using Implementation Framework

• WVU15HSC21

  Protocol 1 Longitudinal Assessment of Immune Response Characterization and Correlates of Protection Among SARS CoV-2 Vaccine Recipients residing in Nursing Home or Assisted Living settings in West Virginia

Refine Search